Olutasidenib

→ Srishti Gupta took over as CEO of Idorsia last summer, but the job is open again as chairman Jean-Paul Clozel kicks off another search. Idorsia’s shares dropped more than 13% on the Swiss exchange when the news broke on Monday. Gupta was called up from the board of directors to replace André Muller , who retired in July 2025 after just a year in the top spot. During Muller’s brief tenure, Idorsia came up empty on a proposed licensing deal for Tryvio , but the FDA gave the green light for its updated label , saying the blood pressure medicine didn’t need a REMS requirement. → George Eliades hopes to once again give a bounce to Jazz Pharmaceuticals , the oncology and neuro drugmaker that he left in 2024. Eliades is returning to the Irish and US biopharma under his previous title of chief transformation officer. He played a different tune for the past two years, serving as CEO of Mythic Therapeutics , but that bet fizzled out due to lackluster interest from investors in the clinical-stage ADC startup. Now he’s returning to a revamped Jazz to “help accelerate our next phase — sharpening our focus, strengthening execution, and ensuring we’re positioned to deliver meaningful impact for patients and their families,” according to a LinkedIn post. Since his departure in the spring of 2024, Jazz welcomed a new CEO, acquired Chimerix for a now- approved brain tumor treatment, inked the highest priority review voucher sale in a decade, and continued to expand its epilepsy pipeline . → Andy Nixon wrote about his departure from Boehringer Ingelheim on LinkedIn and posted a photo holding a cool going-away present: a Gibson guitar. Nixon spent the last five years as global head of biotherapeutics discovery research at the German pharma giant and had a 17-year career with Dyax . “The unexpected gift of the guitar perfectly highlighted what I’ve always valued during my time at Boehringer: being seen and appreciated as a complete person,” Nixon said, adding, “The genuine appreciation shown at my recent farewell event made leaving a much harder step than I anticipated.” → Purple Biotech ’s Gil Efron will step aside in August after four years as CEO and eight years overall. Efron was elevated to president and CFO in July 2021 and succeeded Isaac Israel as CEO a year later. The Israeli cancer biotech’s lead asset is a trispecific antibody for solid tumors called CAPTN-3 . Efron will stay on the board of directors. → Amphista Therapeutics CSO Louise Modis will now be taking over the company from retiring CEO Antony Mattessich , marking another female chief exec in the biotech circle. Modis joined the UK molecular glue biotech in 2023 after a gig as CSO at Mogrify . Before that, she had a seven-year stint at GSK and an eight-year run with Boehringer Ingelheim. Besides Modis’ appointment, Amphista also announced Patrick Kelly as CMO, having served in the same role at Forma Therapeutics , where he helped lead development of olutasidenib . → Korsana Biosciences , the latest startup out of biologics shop Paragon Therapeutics , has secured a CFO with IPO experience. Mark Vignola departed the CFO post at Terns Pharmaceuticals last winter, months before the drug developer ditched its obesity plans to go all in on cancer. Korsana doesn’t appear to be in immediate need of a finance whiz: The company raised a massive $150 million launch round in the fall of 2025, but waited until last month to unveil its Alzheimer’s ambitions that are eerily similar to Roche ’s late-stage program that penetrates the blood-brain barrier. → AbbVie ’s new head of M&A comes from GSK’s search and evaluation team. Garrett Rhyasen has jumped from the UK pharma giant, which is undergoing a CEO transition, to the Chicago-area drugmaker as VP of business development and acquisitions. Rhyasen is joining one of the most active BD teams in industry. AbbVie is digesting about 30 transactions worth $8 billion over the past two years, as noted by finance chief Scott Reents at Leerink ’s healthcare conference in Miami last week. → Harbour BioMed has named Jenny Xie as chief scientific officer for immunology and head of global external innovation for the Hong Kong-listed biotech with operations across China, Europe and the US. Xie was previously head of discovery immunology at Bristol Myers Squibb , where she spent the past 20 years and worked on “tolerance induction, immune reset and tissue repair,” with tools such as T cell engagers, according to her LinkedIn bio. Harbour has built a suite of partnerships in immunology, including with Xie’s longtime former employer and AstraZeneca . → Australian biotech Mesoblast has welcomed Teresa Montagut as its first head of clinical development and medical affairs. Montagut spent more than five years with Regeneron and had been global head of early pipeline studies in oncology, as well as head of medical affairs for investigator-sponsored studies of gastrointestinal and genitourinary conditions. Mesoblast wants to expand the label for its graft-versus-host disease treatment Ryoncil , the first-ever mesenchymal stromal cell therapy to receive an FDA approval . → We’ve got a few promotions to discuss, starting at Neurocrine . Andrew Ratz has been bumped up to chief technical operations officer after a year as SVP of drug development, delivery and device. He had an assortment of roles over 28 years at Eli Lilly , including SVP, delivery, device and connected solutions. Neurocrine’s Ingrezza is already approved for tardive dyskinesia and for chorea in patients with Huntington’s disease, but the San Diego biotech said in December that the drug flopped in a Phase 3 study for dyskinetic cerebral palsy. → Molecular glue specialist Monte Rosa Therapeutics said in its Q4 update that it has promoted its drug discovery leader Magnus Walter to chief technology officer, and Andrew Funderburk to chief investor relations and strategy officer. Walter is a longtime Lilly veteran who then worked for AbbVie as head of discovery chemistry, screening biology and operations. Funderburk joined Monte Rosa in 2024 as SVP, investor relations and strategic finance. Back in September, Novartis shelled out $120 million upfront for its second molecular glue deal with Monte Rosa in as many years. → Ajay Nirula has catapulted to president of Recludix Pharma and will continue to lead R&D, while the San Diego biotech has also promoted Catherine Bovenizer to CFO. Bovenizer held this position at Renova Therapeutics before she jumped to Recludix in 2020, and she had been SVP of finance and business operations since 2022. Peer Review told you about Nirula’s appointment as head of R&D in 2024, ending an eight-year run with Lilly. Recludix has been dosing healthy volunteers for a Phase 1 study of its Sanofi – partnered STAT6 inhibitor REX-8756 , good for a $20 million milestone payment. → IsomAb has a new CEO : Philip Brainin will now be steering the ship of the UK biotech, succeeding Jackie Turnbull . Brainin spent eight years on the medical side of things in Region Hovedstaden and previously was with Sound Bioventures , where he helped advise companies including Boost Pharma , VarmX and AnaCardio . Besides Brainin, IsomAb has also swapped out chairman Paul Edwards , who will remain on the board, with Anker Lundemose . → Cambridge, UK-based Alchemab Therapeutics has recruited Ulrich Wendt as CBO, ending a 25-year career with Sanofi in numerous capacities. He was global head of business development for the French pharma’s immunology & inflammation franchise for the past six years. Alchemab’s ALS candidate ATLX-1282 is at the heart of a licensing deal with Lilly that could be worth as much as $415 million. → Bispecific antibody developer Bambusa Therapeutics has welcomed Todd James as CFO. James was SVP, corporate affairs and investor relations at Viridian and from 2015-21 he was with Acceleron , where he helped secure more than $1 billion in financing. Bambusa was founded by BioNTech veterans Shanshan Xu and Helmut Jeggle and collected $140 million in Series A financing last year. The money will be used to fund clinical- and early-stage candidates, including dermatology and respiratory drugs BBT001 and BBT002 . → Early cancer detection company ClearNote Health has rolled out Jeffrey Venstrom as CMO. Ventstrom served in the same role at cancer screening company Grail , which last week announced that its CEO Bob Ragusa was retiring . Besides Ventstrom, ClearNote also hired Daniel Black as general manager of international markets, Jeremy Bennett as head of marketing, and promoted Irene Hsieh to VP of regulatory affairs and quality assurance. → Besides collecting $40 million this week, Mestag Therapeutics has also brought on Lindsey Rolfe as CMO and Pascal Merchiers as chief development officer. Rolfe served in the same role at both radiotherapy company 3B Pharmaceuticals and Clovis Oncology , where she helped secure marketing approvals in the US and Europe for Rubraca in ovarian and prostate cancer. Meanwhile, Merchiers has served in roles at Commit Biologics , Oncurious , Roche-acquired Tusk Therapeutics and Galapagos . The cash injection will help fund Mestag’s Phase 1 trial, slated to start in mid-2026, which will evaluate its candidate MST-0312 in cancer. → Virginia-based CDMO Phlow has plucked up Dawn Von Rohr as COO. Von Rohr joins the team after a stint as life sciences division president of Pace Life Sciences . Von Rohr had a long career at Mallinckrodt , ending a 22-year run with the company with her role as VP and general manager, global APIs. Last July, Phlow picked up $37 million in a Series C raise, looking to expand its API and key starting material manufacturing capacity in the US. → One of the industry’s longest-tenured investors, Frazier Life Sciences , has a fresh face in its biotech-building shop. Mansi Shinde is now VP of company creation at the firm. She was in corporate development roles at Nvelop Therapeutics and then carried on those duties when it merged with Chroma Medicine to become nChroma . Shinde helped form new biotech companies during a couple-year stint at 4:59 , the incubator unit of 5AM Ventures . She will be based in Frazier’s Boston office alongside colleagues Lauren Mifflin and Joe Cabral . The Frazier ecosystem is massive, with more than $5 billion in capital spread across both venture-backed startups and publicly traded life sciences companies. → Vertex Ventures has lost managing director Christine Brennan to another life sciences investor. Brennan departed the Temasek – backed firm to return to the corporate venture capital and large pharma strategy side of the industry. This week, she joined Johnson & Johnson Innovation , or JJDC , as a partner in the healthcare giant’s Cambridge office. As Brennan wrote in a LinkedIn post , she has “huge shoes to fill” in succeeding Marian Nakada , who left in September after more than a dozen years working on investing strategy at one of the oldest corporate venture arms in existence. Brennan has worked in CVCs before, having spent multiple years at Merck and Novartis’ units. → Royalty Pharma is in Peer Review for the second time this month as the royalty aggregator poaches a bulge bracket banker to help expand its portfolio. Greg Butz , Bank of America ’s global co-head of healthcare investment banking, will become EVP of partnering and investments at Royalty. The firm added a head of Asia this spring, plucking Kenneth Sun from Morgan Stanley . Meanwhile, Royalty said five-year company veteran Chris Hite is now its chair of partnering and investments. The Citi alum just picked up a board seat at Vera Therapeutics . → CSL Behring’s Korean subsidiary has recruited Se-eun Hwang as its new manager. Hwang was previously general manager of Biogen Korea and held roles at Abbott Korea and JW Pharmaceutical . Earlier this week, CSL announced that its hemophilia B gene therapy Hemgenix was temporarily out of stock , warning that some patients would experience delays in treatment. → Synthetic biology company Antheia has picked up Chris Savile as VP, business development and partnerships. Savile spent six years as CEO of Willow Biosciences , which sold its operating subsidiary in 2025 to become Evolutia Bio , while the rest of the company rebranded as Atlas Energy Corp and pivoted to international oil and gas royalty. Savile also previously held roles at Intrexon and Codexis . Antheia, which is partnered with Ginkgo Bioworks , hauled in $56 million in a Series C financing round last year to commercialize its API product thebaine , boost its US capacity and expand into Singapore. → Stockholm-based pediatric skeletal disease biotech Boost Pharma has enlisted Elaine Jones as chair of its board. Jones succeeds Ingelise Saunders , who will remain on the board. Jones’ résumé is stacked with board seats, including at CytomX , NextCure and Gritstone bio . Now led by former Galecto CEO Hans Schambye , Boost is developing a cell therapy for osteogenesis imperfecta, a rare bone disease with no approved treatments. → Radiopharma biotech Convergent Therapeutics has added former Y-mAbs CEO Michael Rossi to its board of directors. Rossi’s 30-year experience in radiopharmaceuticals through his previous roles — including Mirion Technologies , Advanced Accelerator Applications and Jubilant Radiopharma — will help the company and its radioantibody candidate CONV01-α , which is finishing up its Phase 2 trial in metastatic castration-resistant prostate cancer. → Muna Therapeutics CEO Rita Balice-Gordon has joined the board of directors at Lundbeck . Balice-Gordon started with Muna in 2020 as CSO before taking the top exec spot the next year. Under her leadership, Muna forged a pact with GSK in Alzheimer’s in 2024. Earlier this month, Lundbeck CEO Charl van Zyl told Endpoints News’ Zach Brennan that the company would not be forging a “most favored nation” deal with the White House, but instead would participate in one of the CMS pilots.

Strengthening the clinical leadership as the Company progresses to the clinic with its BRD9 Targeted Glue™, AMX-883, in acute myeloid leukemia Amphista continues to advance its SMARCA and TEAD programs to key inflection points Cambridge, UK, 18 th March 2026 – Amphista Therapeutics Ltd. (the “Company” or “Amphista”), a leader in the discovery and development of next generation targeted protein degradation (TPD) medicines, today announces the appointment of Louise Modis, Ph.D., as its Chief Executive Officer (CEO) and member of the Board of Directors, and Patrick Kelly M.D. as its Chief Medical Officer (CMO). Dr. Modis succeeds Antony Mattessich who is retiring. Dr. Modis joined Amphista in May 2023 as Chief Scientific Officer. She is an accomplished leader who brings a combination of deep scientific expertise and strategic focus to the role, gained from over two decades of experience advancing innovative medicines into the clinic across biotech and pharma. She has been instrumental in driving Amphista’s progress to date, having defined the Company’s R&D strategy and building its strong pipeline. Dr. Modis will continue to provide scientific leadership while guiding the Company’s strategic direction. Dr. Kelly joins Amphista and strengthens the clinical leadership as the Company enters the clinic with AMX-883 in acute myeloid leukemia (AML). He brings 35 years of clinical research and clinical practice experience, most recently serving as CMO at Forma Therapeutics where he led the development of olutasidenib, which is now approved for the treatment of IDH1-mutated AML. Dr. Kelly will play a pivotal role in leading the clinical development team and shaping Amphista’s development strategy across the pipeline. Joshua Brumm, Chairman of Amphista’s Board of Directors said : “The Board is delighted to announce the appointments of Louise as CEO and Patrick as CMO. We have been impressed with Louise’s vision and execution of Amphista’s science strategy, and her appointment reflects our confidence in her leadership as we transition to be a clinical-stage company. Combined with Patrick's clinical expertise, Amphista is well positioned to successfully deliver our differentiated pipeline to patients. On behalf of the Board, I would also like to thank Antony for his contributions and wish him the best in his retirement.” Louise Modis, Chief Executive Officer of Amphista, commented : “I’m honored to lead Amphista. As CEO, my priority is to ensure we deliver clinical excellence for AMX-883 and to accelerate our earlier programs into the clinic. With the addition of Patrick as CMO, and the strength of our leadership team, we are well positioned to execute our clinical strategy and advance our BRD9, SMARCA, and TEAD programs for patients and their families.” Patrick Kelly, Chief Medical Officer of Amphista, commented , "I am excited to join Amphista as the Company prepares to enter the clinic with AMX-883 on the back of impressive pre-clinical data. I look forward to working with Louise and the team to deliver the AMX-883 clinical program in AML and building a robust clinical strategy across the broader pipeline.” As a karyotype-independent, pro-differentiation agent, AMX-883 has the potential to transform the treatment paradigm for AML. Amphista expects to submit the Investigational New Drug application to the US Food and Drug Administration for AMX-883 in April and to start its clinical trial in H2 2026. Amphista is developing potent, selective, orally bioavailable degraders of SMARCA2 and TEAD. The Company remains on track to deliver a shortlist of best-in-class compounds later this year for further profiling ahead of candidate nomination. Ends Amphista Therapeutics At Amphista Therapeutics, we are focused on transforming the lives of patients with severe diseases, including cancer and neurodegenerative disorders, through the discovery and development of advanced, next generation targeted protein degradation (TPD) medicines. Amphista applies its proprietary Eclipsys® platform to generate unique, sequentially bifunctional Targeted Glue™ therapeutics with a differentiated mechanism and leading drug-like properties. Our portfolio offers the potential to deliver first- and/or best-in-class therapeutics with performance characteristics beyond the limitations of CRBN and VHL-based agents. Amphista was co-founded by Advent Life Sciences and is additionally funded by a premier group of investors including Forbion, Gilde Healthcare, Novartis Venture Fund, SV Health Investors’ Dementia Discovery Fund and Eli Lilly. For more information, please visit: Amphista, Eclipsys, Targeted Glue, Targeted Glues and the Amphista logo are all trademarks or registered trademarks of Amphista Therapeutics Limited. For more information please contact: Amphista Therapeutics John Goodall Email: Info@amphista.com ICR Healthcare Namrata Taak, Ashley Tapp, Emily Johnson Email: Amphista@icrhealthcare.com Tel: +44 (0)20 3709 5813